Dennis Kim

Dennis Kim, MD, PhD

My research is aiming to develop projects of: 1) biomarker discovery using genomics in leukemias and allogeneic stem cell transplantation; and 2) clinical research in chronic myeloid leukemia and graft-versus-host disease after allogeneic stem cell transplantation.

I have also been involved in multiple exome sequencing projects in acute myleoid leukemia (AML) with normal karyotype and secondary AML progressed from antecedent hematologic malignancies, as well as chronic myeloid leukemia (CML). My future direction of genomic research is to integrate multi-omics platforms to investigate leukemia genomes, thus dissecting clonal structures in a refined way.

Not only in translational research, but also in the clinical research field, I have shown significant progress in three ways: 1) clinical database registry; 2) retrospective studies using the database; and 3) generation of prospective clinical trials in CML and in graft-versus-host disease (GVHD) and other post-transplant complications after allogeneic stem cell transplantation.  First of all, I developed a clinical database of allogeneic transplant patients (especially for GVHD and post-transplant complications) and CML patients (especially for treatment outcomes after tyrosine kinase inhibitor therapy). Secondly, I have participated in multiple ongoing clinical retrospective studies generated from the registry database. Thirdly, I am involved in  multiple clinical trials. Currently, I am the principal investigator of a pivotal Canadian tyrosine kinase inhibitor (TKI) discontinuation clinical trial and am also a chair of the correlative part of this trial, entitled "Treatment-free Remission Accomplished with Dasatinib (TRAD)". This is the first Canadian TKI discontinutation trial for the management of CML.
Tissue Cell. 2017 Dec;49(6):680-690
Han KH, Kim AK, Kim MH, Kim DH, Go HN, Kang D, Chang JW, Choi SW, Kang KS, Kim DI
Haematologica. 2017 Nov;102(11):e434-e437
Kim HS, Oh SH, Kim JH, Kim JY, Kim DH, Lee SJ, Choi SU, Park KM, Ryoo ZY, Park TS, Lee S
Leukemia. 2017 Sep;31(9):1992-1995
Ha JS, Do YR, Ki CS, Lee C, Kim DH, Lee W, Ryoo NH, Jeon DS
Antivir Ther. 2017 Mar 31;:
Lam W, Al-Shaibani Z, Kumar D, Viswabandya A, Thyagu S, Michelis FV, Kim DD, Lipton JH, Messner HA, Deotare U
J Hum Genet. 2016 Oct;61(10):885-889
Jin DH, Kim S, Kim DH, Park J
Int J Cancer. 2017 Jan 01;140(1):86-94
Park C, Kim JI, Hong SN, Jung HM, Kim TJ, Lee S, Kim SJ, Kim HC, Kim DH, Cho B, Park JH, Sung J, Lee DS, Kang M, Son HJ, Kim YH
J Gerontol A Biol Sci Med Sci. 2017 Aug 01;72(8):1038-1044
Donlon TA, Morris BJ, He Q, Chen R, Masaki KH, Allsopp RC, Willcox DC, Tranah GJ, Parimi N, Evans DS, Flachsbart F, Nebel A, Kim DH, Park J, Willcox BJ
PLoS One. 2015;10(9):e0137657
Jin DH, Park SE, Lee J, Kim KM, Kim S, Kim DH, Park J
Oncotarget. 2015 Aug 21;6(24):20190-203
Jin DH, Lee J, Kim KM, Kim S, Kim DH, Park J
Oncotarget. 2015 Sep 15;6(27):24499-510
Park K, Choi MK, Jung HH, Do IG, Lee KH, Ahn T, Kil WH, Kim SW, Lee JE, Nam SJ, Kim DH, Ahn JS, Im YH, Park YH